Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive Cardiopulmonary exercise testing

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Dumitrescu, Daniel ^a,b   Oudiz, Ronald J ^a,b   Karpouzas, George ^a,b   Hovanesyan, Arsen ^a,b   Jayasinghe, Amali ^a,b   Hansen, James E ^a,b   Rosenkranz, Stephan ^b   Wasserman, Karlman ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; OXYGEN;

ADULT; AEROBIC EXERCISE; ARTICLE; BREATHING MECHANICS; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC VALUE; END TIDAL CARBON DIOXIDE TENSION; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG VENTILATION PERFUSION RATIO; MALE; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RESPIRATORY TRACT PARAMETERS; SYSTEMIC SCLEROSIS; VENOUS OXYGEN TENSION; ALGORITHM; EXERCISE TEST; LUNG DISEASE; METABOLISM; METHODOLOGY; PATHOLOGY; PERFUSION; PULMONARY ARTERY; PULMONOLOGY; VASCULAR DISEASE;

ALGORITHMS; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; OXYGEN; PERFUSION; PROSPECTIVE STUDIES; PULMONARY ARTERY; PULMONARY GAS EXCHANGE; PULMONARY MEDICINE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 78650785102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014293     Document Type: Article

References (28)

1. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, et al. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary hypertension: application of a registry approach. Ann Rheum Dis 62: 1088-1093.
2. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM (2008) Exercise-induced pulmonary arterial hypertension. Circulation 118: 2183-2189.
3. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, et al. (2009) Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 180(9): 881-886.
4. Miyauchi T, Yorikane R, Sakai S, et al. (1993) Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73: 887-897.
5. Nishida M, Eshiro K, Okada Y, Takaoka M, Matsumura Y (2004) Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotalineinduced pulmonary hypertension. J Cardiovasc Pharmacol 44: 187-191.
6. Galiè N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371: 2093-2100.
7. Sun XG, Oudiz RJ, Hansen JE, Wasserman K (2001) Exercise Pathophysiology in Primary Pulmonary Vascular Hypertension. Circulation 104: 429-435.
8. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects (2008) Available: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 2010 Nov 19.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (1980) Arthritis Rheum 23: 581-590.
10. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117.
11. Huszczuk A, Whipp BJ, Wasserman K (1990) A respiratory gas exchange simulator for routine calibration in metabolic studies. Eur Respir J 3: 465-468.
12. Beaver WL, Wasserman K, Whipp BJ (1986) A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 60: 2020-2027.
13. Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N (1985) Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 131: 700-708.
14. Davis JA, Storer TW, Caiozzo VJ (1997) Prediction of normal values for lactate threshold estimated by gas exchange in men and women. J Appl Cardiol 76: 157-164.
15. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ (2005) Measurements During Integrative Cardiopulmonary Exercise Testing. In: Principles of Exercise Testing and Interpretation. 4th ed. Philadelphia: Lippincott Williams & Wilkins. pp 104-106.
16. Hansen JE, Sun XG, Yasunobu Y, Garafano RP, Gates G, et al. (2004) Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest 126;. pp 816-824.
17. Hansen JE, Ulubay G, Chow BF, Sun XG, Wasserman K (2007) Mixed-expired and end-tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Chest 132: 977-983.
18. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K (2005) End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest 127: 1637-1646.
19. Hansen JE, Wasserman K (1996) Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 109: 1566-1576.
20. Schwaiblmair M, Behr J, Fruhmann G (1996) Cardiorespiratory Responses to incremental exercise in patients with systemic sclerosis. Chest 110: 1520-1525.
21. Wasserman K, Sun XG, Hansen JE (2007) Effect of biventricular pacing on the exercise pathophysiology of heart failure. Chest 132: 250-261.
22. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, et al. (2000) Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101: 2803-2809.
23. Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, et al. (2002) Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation 106: 3079-3084.
24. Deboeck G, Niset G, Lamotte M, Vachiery JL, Naeije R (2004) Exercise testing in pulmonary arterial hypertension and in chronic heart failure. Eur Respir J 23: 747-751.
25. Markowitz DH, Systrom DM (2004) Diagnosis of Pulmonary Vascular Limit to Exercise by Cardiopulmonary Exercise Testing. J Heart Lung Trans 23: 88-95.
26. Sun XG, Hansen JE, Garatchea N, Storer TW, Wasserman K (2002) Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med 166: 1443-1448.
27. Montani D, O'Callaghan DS, Savale L, Jaïs X, Yaïci A, et al. (2010) Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 104(Suppl 1): S23-32.
28. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, et al. (2008) Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 87(4): 220-233.